Neurocrine Biosciences, Inc.

NBIXNASDAQHealthcare● Active

$162.57

$-1.31(-0.80%)

Market Cap$16.3B

P/E Ratio—

52W High$168

52W Low$122.14

Avg Volume1.2M

Open$163.88

Beta0.40

Free Cash Flow Financials Revenue

Neurocrine Biosciences, Inc. (NBIX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

NBIX · free cash flow · updated Jun 8, 2026

Core FCF metrics

NBIX · FCF · TTM · margin & CAGR

Free cash flow was $748.7M for FY2025 (fiscal year ending 2025-12-31), up 34.4% year-over-year The FCF margin was 26.2%. Five-year CAGR stands at +28.0%.

FY2025 Free Cash Flow$748.7M▲ +34.4% YoY

Trailing 12M (TTM)$831.3Mtrailing 4 quarters sum

FCF Margin26.2%$748.7M ÷ revenue

3-Year CAGR+32.4%FY2022 → FY2025

5-Year CAGR+28.0%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

NBIX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$782.7M(34M)$748.7M▲ +34.4%26.2%

FY2024$595.4M(38M)$557.2M▲ +54.1%23.7%

FY2023$389.9M(28M)$361.6M▲ +12.0%19.2%

FY2022$339.4M(17M)$322.9M▲ +38.5%21.7%

FY2021$256.5M(23M)$233.1M▲ +7.1%20.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

NBIX · P/FCF · FCF yield · FCF per share

Neurocrine Biosciences, Inc. (NBIX) trades at a FCF yield of 5.04% and a price-to-free-cash-flow ratio of 19.5x. FCF per share stands at $8.35, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.04%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$8.35

TTM FCF ÷ Shares Outstanding

Price / FCF

x19.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x20.0

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

NBIX · cash flow statement · operating / investing / financing

For FY2025, Neurocrine Biosciences, Inc. generated $782.7M in operating cash flow and spent 34M in capital expenditures, yielding $748.7M in free cash flow.

Operating Activities

+$782.7M

Cash from core business operations

2025-12-31

Investing Activities

−$264.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$38.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($782.7M) − |CapEx| (34M) = FCF ($748.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

NBIX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Neurocrine Biosciences, Inc.YOU

NBIX

$748.7M+34.4%26.2%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Neurocrine Biosciences, Inc. (NBIX) reported free cash flow of $748.7M for FY2025 (fiscal year ending 2025-12-31), up 34.4% year-over-year. The FCF margin was 26.2%.

Based on available data, Neurocrine Biosciences, Inc. has maintained positive free cash flow for at least 8 fiscal year(s). FCF peaked at $748.7M in FY2025. The 5-year CAGR stands at +28.0%.

Neurocrine Biosciences, Inc.'s FCF yield is 5.04% and price-to-FCF ratio is 19.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

NBIX free cash flow · 8 questions

Neurocrine Biosciences, Inc. free cash flow was $748.7M for FY2025, up 34.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $831.3M.

NBIX free cash flowNBIX FCFNBIX FCF 2025NBIX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Neurocrine Biosciences, Inc. · Neurocrine Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026